Zoledronic and Hyperthyroidism - a phase IV clinical study of FDA data

Summary:

Hyperthyroidism is reported as a side effect among people who take Zoledronic (zoledronic acid), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Femara, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Hyperthyroidism when taking Zoledronic. It is created by eHealthMe based on reports of 29,760 people who have side effects when taking Zoledronic from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Hyperthyroidism?

Hyperthyroidism (over activity of the thyroid gland) is found to be associated with 1,032 drugs and 1,426 conditions by eHealthMe. Check the latest studies of Hyperthyroidism.

On Jan, 29, 2026

29,760 people reported to have side effects when taking Zoledronic.
Among them, 28 people (0.09%) have Hyperthyroidism.

Among these 28 people:

How long have people been on Zoledronic when they have Hyperthyroidism? *

What is the gender of people who have Hyperthyroidism when taking Zoledronic? *

female: 76 %
male: 24 %

What is the age of people who have Hyperthyroidism when taking Zoledronic? *

What are other drugs people take besides Zoledronic? *

What are other side effects people have besides Hyperthyroidism? *

Hypocalcaemia (levels of calcium in blood serum are abnormally low): 8 people, 28.57%
Hypernatraemia (an abnormally high plasma concentration of sodium ions): 8 people, 28.57%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 8 people, 28.57%
Diabetes Insipidus - Nephrogenic (diabetes caused by a deficiency of the pituitary hormone vasopressin, which regulates kidney function): 7 people, 25.00%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 7 people, 25.00%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 7 people, 25.00%
Nausea (feeling of having an urge to vomit): 5 people, 17.86%
Rashes (redness): 5 people, 17.86%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 17.86%
Cough: 4 people, 14.29%

What are the existing conditions these people have? *

Hypercalcaemia (elevated calcium (ca+) level in the blood): 9 people, 32.14%
Bipolar Disorder (mood disorder): 7 people, 25.00%
Breast Cancer Metastatic: 5 people, 17.86%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 4 people, 14.29%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 4 people, 14.29%
Hyperchlorhydria (gastric acid levels are higher in stomach): 4 people, 14.29%
Flatulence (flatus expelled through the anus): 4 people, 14.29%
Liver Disorder (liver diseases): 3 people, 10.71%
Sleep Disorder: 3 people, 10.71%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and have Hyperthyroidism?

- Check whether Hyperthyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic:

Zoledronic (29,812 reports)

Hyperthyroidism treatments and more:

Hyperthyroidism (26,829 reports)

Browse all side effects of Zoledronic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperthyroidism:

Hyperthyroidism (1,032 drugs)

Browse all the conditions that are associated with Hyperthyroidism:

Hyperthyroidism (1,426 conditions)

Related publications that referenced our studies

Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .
Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic) and Zoledronic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.